Scientific Content Strategist and Writer

Fremont, CA (On-site)

$128K/yr – $160K/yrMid Level8+ years expFull time

Posted 3 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Drive and govern global scientific content strategy as a senior writer, owning high-impact technical assets and governance.

  • Own high-impact technical assets and set strategic roadmap.
  • Must-have: 8+ years leading scientific content strategy in regulated environments.
  • Standout: final technical authority for customer-facing materials.

Job Description

Responsibilities

  • Independently author, high-impact technical assets (e.g., whitepapers, thought leadership pieces, or executive-level materials) where deep subject matter expertise is required.
  • Provide strategic technical review and guidance, focusing on scientific integrity and alignment with approved messaging frameworks.
  • Edit and refine existing materials for grammar, style, and brand alignment.
  • Partner with Product Marketing, Sales, Applications, and Campaign Leads to identify content gaps, prioritize initiatives, and define content roadmaps.
  • Advise internal teams on best practices for technical storytelling and scientific communication.
  • Translate business objectives and campaign strategies into technical content plans, rather than executing ad hoc writing requests.
  • Provide strategic direction and feedback to internal contributors for content execution.
  • Design and continuously improve scalable content development processes, enabling efficient collaboration.
  • Define success metrics for technical content effectiveness (e.g., engagement) and use insights to inform future strategy.
  • Serve as the final technical authority for high-impact customer-facing content.
  • Other duties as assigned.
Cytek Biosciences Inc logo

Cytek Biosciences Inc

3.4 Glassdoor

Cytek® Biosciences Inc. is a leading manufacturer and supplier of flow cytometry products and services. Cytek’s compact, affordable instruments and wide ranging support offerings are used by researchers and clinicians all over the world. Flow cytometry is a powerful analytical tool used for identifying and quantifying cellular characteristics on a cell-by-cell basis up to tens of thousands of cells per second. This technology is used in research and clinical studies with various biomedical and therapeutic applications such as investigating the role of the body’s immune system in fighting cancer, diagnosing leukemia and lymphoma, and detecting minimal residual disease in organ transplant patients. Flow cytometry has many advantages over traditional microscopy since it enables the analysis of a greater number of cells in a fraction of the time. At Cytek, we are focused on accelerating the adoption of flow cytometry for one simple reason: to fuel scientific discovery. We have leveraged our highly experienced, best-in-the-business team to bring forth an innovative new class of flow cytometry solutions. These solutions deliver deep biological insights at an affordable price, provide high-end capabilities, and bring simplified workflows to more researchers than ever before. As a company, we also seek to maintain high ethical standards and a culture that values honesty, integrity and transparency in all that we do. Company decisions are driven by what is right for scientific discovery and customer support. We are committed to our employees, to the environment in which we live and to the communities we serve worldwide. Cytek is headquartered in Fremont, California with branch offices and distribution channels across the globe. For more information, visit www.cytekbio.com.

Founded in 1992
Fremont, California, USA
445 employees (11 in marketing)
52% recommend to a friend
100% CEO approval

Traffic Signals

Monthly Visitors
70K
Monthly Google Ads Budget
$6.6K
Traffic Source Mix
Search
48.7%
Direct
42.9%
Referral
6.2%
Social
1.1%
Paid
0.9%

Headcount Trend

Current headcount: ~445

Marketing Team

Marketing Team Size
11 (2% of company)

Funding

Total Funding
$144.3M
Last Raise
$120M
Series D, 6 years ago

Funding History

  • Nov 2020
    Series D • $120M
  • Sep 2018
    Series C
  • Jan 2017
    Series B • $12M

Recent News